AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Aldo-keto reductase family 1 member C1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q04828

UPID:

AK1C1_HUMAN

Alternative names:

20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; Dihydrodiol dehydrogenase 1; High-affinity hepatic bile acid-binding protein

Alternative UPACC:

Q04828; P52896; Q5SR15; Q7M4N2; Q9UCX2

Background:

Aldo-keto reductase family 1 member C1, known by alternative names such as 20-alpha-hydroxysteroid dehydrogenase and High-affinity hepatic bile acid-binding protein, plays a crucial role in the metabolism of hormones including estrogens and androgens. It catalyzes the reduction of ketosteroids to hydroxysteroids, displaying broad positional specificity and affinity for bile acids.

Therapeutic significance:

Understanding the role of Aldo-keto reductase family 1 member C1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.